Latest Publication:

Randomized, observer-blind, controlled Phase 1 study of the safety and immunogenicity of the Na-GST-1/Alhydrogel hookworm vaccine with or without a CpG ODN adjuvant in hookworm-naïve adults
Research News

The GW VRU is proud to announce our newest publication to describe the development of a new Na-GST-1/Alhydrogel hookworm vaccine. This was a Phase 1 randomized study to demonstrate the safety with promising results and can be read at the link below: 

Click here to read the full article
vaccine

Latest News

marburg virus
Marburg outbreak is reported in Uganda, threatening to complicate Ebola response in region
Uganda has detected what appears to be a localized outbreak of Marburg virus disease, with two cases identified in a single family, according to a source familiar with the situation, although the Ugandan government had not yet publicly confirmed the outbreak at the time of publication. The…
GW's David Diemert interviews for Beacon Magazine
GW VRU tests Pfizer's new vaccine for C. diff
The GW VRU is a site for a clinical trial to examine Pfizer's new C. diff vaccine.
Picture of small pox with the outer and inner core
Results show safety and immunogenicity of fractional doses of the MVA-BN mpox vaccine
This was a phase 2, randomized, open-label, non-placebo controlled trial to evaluate two partial doses o the Modified Vaccinia Ankara-Bavarian Nordin (MVA-BN) vaccine for protection against mpox.